U.S., Jan. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07313007) titled 'Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD' on Dec. 11, 2025.
Brief Summary: Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver disorders ranging from simple steatosis-a relatively benign and non-progressive condition-to metabolic dysfunction-associated steatohepatitis (MASH), characterized by hepatocellular inflammation. MASLD is now the leading cause of chronic liver disease worldwide, affecting approximately one in three adults, particularly those with obesity or type 2 diabetes.
Recent studies have highlighted a strong interconnection...